Oncology-New York最新文献_第4页

Exploring the Changing Diagnostic Criteria of Gorlin-Goltz Syndrome: A Case Report. 探讨Gorlin-Goltz综合征诊断标准的变化:1例报告。

4区医学

Oncology-New York Pub Date : 2023-11-08 DOI: 10.46883/2023.25921007

Sahith Kumar Shetty, Vidya G Doddawad, Shyam Sundar, Shivananda S

引用次数: 0

Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman. 一位年轻女性透明细胞肉瘤的不寻常临床表现。

4区医学

Oncology-New York Pub Date : 2023-10-10 DOI: 10.46883/2023.25921005

Samia Asif, Brendan J Hurley, Sehr Haroon, Subodh Lele, Bhavina Sharma

{"title":"Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman.","authors":"Samia Asif, Brendan J Hurley, Sehr Haroon, Subodh Lele, Bhavina Sharma","doi":"10.46883/2023.25921005","DOIUrl":"10.46883/2023.25921005","url":null,"abstract":"Clear cell sarcoma (CCS) is a rare but aggressive malignancy that typically occurs in young adults and is characterized by soft tissue tumors of the extremities. CCS can be difficult to distinguish from metastatic melanoma based solely on histology and immunohistochemistry (IHC) because of the significant overlap between them. However, it is imperative to get an accurate clinical diagnosis, as it informs disease staging and treatment options for patient care. Present in approximately 75% of CCS cases, the EWSR1 gene rearrangement detected by fluorescence in situ hybridization (FISH) can help with establishing a diagnosis; the underlying reciprocal translocation has never been reported in cutaneous melanoma. We reviewed a case of a young woman who presented with a confusing picture of widespread lymphadenopathy, cutaneous metastases, and electrolyte derangements and was subsequently diagnosed with metastatic CCS.This case suggests possible value in performing molecular testing when a clinical picture does not correspond with what is expected for melanoma. It also raises the question of whether CCS cases may be underreported. This case highlights an uncommon presentation that may not be recognized as a manifestation of CCS by an oncologist who is not a sarcoma specialist. It is unclear how COVID-19 vaccination contributed to her clinical presentation, and it is also unclear whether an early diagnosis would have changed her clinical outcome.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"37 10","pages":"412-416"},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma. 达拉单抗/透明质酸酶治疗多发性骨髓瘤期间继发性纯红细胞发育不全。

4区医学

Oncology-New York Pub Date : 2023-10-10 DOI: 10.46883/2023.25921006

Ludovic Saba, Kevin S Landau, Silvia Bunting, Chakra P Chaulagain

{"title":"Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma.","authors":"Ludovic Saba, Kevin S Landau, Silvia Bunting, Chakra P Chaulagain","doi":"10.46883/2023.25921006","DOIUrl":"10.46883/2023.25921006","url":null,"abstract":"Predominantly autoimmune in origin, severe normochromic, normocytic anemia with reticulocytopenia in the setting of the normal production of leukocytes and megakaryocytic lineages is known as pure red cell aplasia (PRCA), which is unlike aplastic anemia in which all lineages are affected due to a stem cell defect. PRCA can be primary (such as autoimmune) or acquired, which can be an acute self-limited illness or a chronic disease that may be induced by medications, including immunotherapy such as monoclonal antibodies (mAbs). Daratumumab is a mAb directed against CD38 used for the treatment of multiple myeloma and systemic amyloid light-chain amyloidosis. The intravenous formulation of daratumumab received initial FDA approval, and later approval was received for the subcutaneous formulation daratumumab and hyaluronidase-fihj. The subcutaneous version increases patient convenience and has become the preferred route of administration since its approval. We herein present the case of a patient with multiple myeloma who developed acquired DNMT3A-positive PRCA while transitioning to daratumumab/hyaluronidase after initial treatment with daratumumab.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"37 10","pages":"419-424"},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spinal ATRT and Radiotherapy Case Report in an Adult Man. 一例成年男性脊髓ATRT和放射治疗病例报告。

4区医学

Oncology-New York Pub Date : 2023-09-13 DOI: 10.46883/2023.25921004

Fatma Betül Ayrak, Süheyla Aytaç Arslan, Yılmaz Tezcan

引用次数: 0

Active Surveillance of Prostate Cancer. 前列腺癌的主动监测。

4区医学

Oncology-New York Pub Date : 2017-01-15

Peter L Choyke, Stacy Loeb

引用次数: 0

Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies. 免疫疗法：治疗妇科恶性肿瘤的新策略。

4区医学

Oncology-New York Pub Date : 2016-01-01

Ariel Bulua Bourla, Dmitriy Zamarin

引用次数: 0

Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. 运动在癌症发生和发展过程中对炎症-免疫轴功能的调节作用

4区医学

Oncology-New York Pub Date : 2015-12-01

Graeme J Koelwyn, Erik Wennerberg, Sandra Demaria, Lee W Jones

引用次数: 0

Advances in the systemic treatment of metastatic melanoma. 转移性黑色素瘤的系统治疗进展。

4区医学

Oncology-New York Pub Date : 2013-05-01

Melinda Yushak, Harriet M Kluger, Mario Sznol

{"title":"Advances in the systemic treatment of metastatic melanoma.","authors":"Melinda Yushak, Harriet M Kluger, Mario Sznol","doi":"","DOIUrl":"","url":null,"abstract":"Prior to 2011, the only commercially available agents commonly used to treat metastatic melanoma-including dacarbazine, temozolomide (Temodar), fotemustine, carboplatin, paclitaxel, and interleukin-2-demonstrated limited efficacy, and no study involving these agents had shown an improvement in overall survival. The standard of care for the treatment of metastatic melanoma was radically changed by the subsequent approval of two agents, ipilimumab (Yervoy) and vemurafenib (Zelboraf), both of which improved survival in randomized phase III trials. Within the relatively short time that ipilimumab and vemurafenib have been commercially available, phase II data for the investigational agents nivolumab and MK-3475, for the combination of dabrafenib and trametinib, and for adoptive cell therapy strongly suggest even further improvements in treatment outcomes. Within this rich context of effective agents, the challenge for clinicians and investigators will be to develop predictive biomarkers of response, the optimal sequence of therapy for individual patients, and effective combinations. An additional challenge will be to find the appropriate venue and populations to test promising new agents arising from substantial advances in our understanding of molecular alterations in melanoma cells, of mechanisms of resistance to current agents, and of tumor-host immune interactions.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"27 5","pages":"374-81"},"PeriodicalIF":0.0,"publicationDate":"2013-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092183/pdf/nihms-982755.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41106172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Milk thistle. 奶蓟草

4区医学

Oncology-New York Pub Date : 2008-10-01

Barrie Cassileth

引用次数: 0

Understanding and treating triple-negative breast cancer. 了解和治疗三阴性乳腺癌。

4区医学

Oncology-New York Pub Date : 2008-10-01

Carey Anders, Lisa A Carey

{"title":"Understanding and treating triple-negative breast cancer.","authors":"Carey Anders, Lisa A Carey","doi":"","DOIUrl":"","url":null,"abstract":"Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile, aggressive behavior, distinct patterns of metastasis, and lack of targeted therapies. Although not synonymous, the majority of triple-negative breast cancers carry the \"basal-like\" molecular profile on gene expression arrays. The majority of BRCA1-associated breast cancers are triple-negative and basal-like; the extent to which the BRCA1 pathway contributes to the behavior of sporadic basal-like breast cancers is an area of active research. Epidemiologic studies illustrate a high prevalence of triple-negative breast cancers among younger women and those of African descent. Increasing evidence suggests that the risk factor profile differs between this subtype and the more common luminal subtypes. Although sensitive to chemotherapy, early relapse is common and a predilection for visceral metastasis, including brain metastasis, is seen. Targeted agents, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and poly (ADP-ribose) polymerase (PARP) inhibitors, are currently in clinical trials and hold promise in the treatment of this aggressive disease.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"22 11","pages":"1233-9; discussion 1239-40, 1243"},"PeriodicalIF":0.0,"publicationDate":"2008-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140102769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0